News | Prostate Cancer | March 22, 2017

Profound Medical Corp. and Philips Announce First TULSA-PRO Sale in Finland

System combines real-time MRI with transurethral, robotically-driven ultrasound for prostate ablation

March 22, 2017 — Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital (“Tyks”). The deal was completed in collaboration with Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.

Profound has also sold TULSA-PRO systems in Spain, the United Kingdom and Germany since receiving CE Mark designation in April 2016.

Operation of the TULSA-PRO system will be administered under Roberto Blanco Sequeiros, M.D., chairman of the Medical Imaging Center at Turku University Hospital and under a leading European urologist, Peter Boström, M.D. According to Blanco Sequeiros, the technology holds promise in multiple areas of prostate treatment and care, including focal therapy for localized prostate cancer, treatment of benign prostate hyperplasia, salvage radiation therapy and the debulking of tumours.

“While there have been significant medical advances in prostate care in recent years, there is no question that an unmet medical need and uncharted medical terrain remains,” commented Blanco Sequeiros. “Survival rates for prostate cancer are high, but current therapies often come with side effects that include erectile dysfunction, incontinence and bowel problems. Though further testing is required, the evidence is compelling, and suggests that the TULSA-PRO system could represent a major breakthrough in prostate treatment, offering patients a therapy that is safe, accurate and effective with minimal side effects. We are keen to assess its potential in both localized prostate cancer and other prostate conditions.”

TULSA-PRO combines real-time magnetic resonance imaging (MRI) with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO has demonstrated accurate and precise ablation of malignant prostate tissue, while providing a favorable safety profile, with low rates of serious or long-term adverse events.

Profound is currently conducting a pilot commercial launch of TULSA-PRO in key European and other CE mark jurisdictions. The company is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology.  If successful, TACT is expected to support Profound's application to the FDA for approval to market TULSA-PRO in the United States.

For more information: www.profoundmedical.com

Related Content

EchoGo Pro automates cardiac ultrasound measurements for heart functions, but also empower physicians to predict the occurrence of coronary artery disease (CAD).

EchoGo Pro automates cardiac ultrasound measurements for heart functions, but also empower physicians to predict the occurrence of coronary artery disease (CAD).

News | Cardiovascular Ultrasound | September 25, 2020
September 25, 2020 — Based on its recent analysis of the global...
The cartilage in this MRI scan of a knee is colorized to show greater contrast between shades of gray.

The cartilage in this MRI scan of a knee is colorized to show greater contrast between shades of gray. Image courtesy of Kundu et al. (2020) PNAS

News | Artificial Intelligence | September 22, 2020
September 22, 2020 — Researchers at the University of Pitts...
According to Philips, MR-STAT is a major shift in MRI, relying on a new, smart acquisition scheme and machine-assisted reconstruction. It delivers multiple quantitative MR parameters in a single fast scan, and represents a significant advance in MR tissue classification, fueling big data algorithms and AI-enabled integrated diagnostic solutions.

Image courtesy of Philips Healthcare

Feature | Magnetic Resonance Imaging (MRI) | September 21, 2020 | By Melinda Taschetta-Millane
A new report,...
Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries

Figure 1. Doppler flows in subpleural consolidation shows smoothly dilated branching arteries 

Feature | Radiology Imaging | September 17, 2020 | By Robert Bard, M.D. PC, DABR, FASLM
COVID-19 is routinely studied using...
Ultrasound-guided carpal tunnel release quickly improves hand function and reduces hand discomfort, making the procedure a safe, effective, and less invasive alternative to traditional open or endoscopic surgery

Patients answered three questionnaires (Quick-Disabilities of the Arm, Shoulder, and Hand [QDASH] and two parts of the Boston Carpal Tunnel Syndrome Questionnaire: symptom severity [BCTSQ-SS] and functional status [BCTSQ-FS] scales) assessing the affected wrist's function and discomfort immediately pre-procedure, 2 weeks post-procedure, and at least one year post-procedure. Infographic courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Ultrasound Imaging | September 17, 2020
September 17, 2020 — According to ARRS' American Journal of Roentgenology (AJR),...
Feature | Coronavirus (COVID-19) | September 15, 2020
September 15, 2020 — The world is facing a global pandemic with unknown implications, but it is now well known ...
Videos | Coronavirus (COVID-19) | September 15, 2020
Case is a 6-month-old infant boy admitted to hospital due to respiratory distress then worsened by a pericardial effu
The Epiq CVxi being used for TEE imaging in the cath lab. The system brings together advanced image quality, quantification and intelligence specifically for the cardiologist.

The Epiq CVxi being used for TEE imaging in the cath lab. The system brings together advanced image quality, quantification and intelligence specifically for the cardiologist.

News | Ultrasound Imaging | September 15, 2020
September 15, 2020 — Philips Healthcare recently introduced the latest addition to its portfolio of dedicated...
 A cardiac MRI is effective in identifying inflammation of the heart muscle in athletes and can help determine when those who have recovered from COVID-19 can safely return to play in competitive sports, according to a new study by researchers at The Ohio State University Wexner Medical Center.

Getty Images

News | Cardiac Imaging | September 14, 2020
September 14, 2020 — A...